IME
Imexhs Limited
๐ฆ๐บ ASX
๐ฉบ HEALTH CARE
๐ Overview
๐ Performance
๐ต Cost
๐ค Advanced
๐จโ๐ฉโ๐งโ๐ฆ Community
๐
+ 271.67%
Annual Growth
5 years average annual growth
๐ต
$ 500
Minimum Order
Due to regulatory requirements
๐
2
Pearlers Invested
Since January 2020
๐ Overview
Key information
๐ Fund Overview
ImExHS Ltd. engages in the development and sale of its Hiruko software platform. The company is headquartered in Mascot, New South Wales and currently employs 400 full-time employees. The company went IPO on 2005-12-14. The firm develops software-as-a-service imaging solutions that includes a Picture Archiving and Communications System (PACS), a Radiology Information System (RIS), a Cardiology Information System (CIS) and an Anatomical Pathology Laboratory Information System (APLIS). Its solutions are cloud-based, vendor neutral and zero footprint, with no need for installed software. Its radiology services provide radiological diagnostic services to hospitals and medical facilities in Colombia and Spain using IMEXHS medical imaging software. The firm's services business also provides it with medical images and radiologists interpretation and reports to develop artificial intelligence (AI) tools. Its solutions include AQUILA - Radiology, ALULA - Pathology, ANTEROS - cardiology, artificial intelligence and advanced visualization.
๐ Performance
Price History
+483.33%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
๐๏ธ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out โ๐ต Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out โโฑ๏ธ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out โ๐ต Costs
๐ผ
N/A
Management Fee
Included in unit price, not charged by Pearler
๐ธ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐ธ Net fee calculator๐ค Advanced information
Technical Info
๐ฐ Price*
$0.35
*Price may be up to 24 hours old
๐ฉโ๐ฉโ๐ฆ Community Insights
How our community is investing
๐ Pearlers invested in IME
2
๐ Total Capital Earnings
$153.66
๐ Average investment frequency
14 weeks
๐ต Average investment amount
$632
โฐ Last time a customer invested in IME
300 days
IME investor breakdown
๐ต Income of investors
More than 200k
33%
150k - 200k
100k - 150k
50k - 100k
67%
Less than 50k
๐ถ Age of investors
18 - 25
26 - 34
35 - 90
100%
๐ Legal gender of investors
Female
50%
Male
50%
Pearlers who invest in IME also invest in...
Wesfarmers Ltd. engages in the provision of fresh food, groceries, general merchandise, liquor, fuel, and financial services. The company is headquartered in Perth, Western Australia and currently employs 120,000 full-time employees. Its segments include Bunnings Group; Kmart Group; Officeworks; Wesfarmers Chemicals, Energy and Fertilisers (WesCEF); Industrial and Safety; Health; Catch; and Other. The Bunnings Group segment is a retailer of building materials and home, garden and lifestyle improvement products. The Kmart Group segment is a retailer of apparel and general merchandise, including toys, leisure, entertainment, home, and consumables. The Officeworks segment is a retailer and supplier of office products and solutions for households, small-to-medium sized businesses, and the education sector. The WesCEF segment is a manufacturer and marketer of chemicals for industry, mining, and mineral processing; manufacturer and marketer of broadacre and horticultural fertilizers; and others.
๐ Performance (5Yr p.a)
19.43%
๐ Share price
$71.49 AUD
๐ HIGH ESG SCORE
๐๏ธ SOCIALLY AWARE
๐๏ธ CONSUMER
๐ HIGH PRICE GROWTH
๐ณ ENVIRONMENTAL
Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The firm is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimerโs Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamemโs mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamemโs therapeutic potential.
๐ Performance (5Yr p.a)
6.90%
๐ Share price
$0.03 AUD
๐ HIGH PRICE GROWTH
๐งฌ BIOTECHNOLOGY
Audinate Group Ltd. engages in the development and commercialization of audio visual software and hardware. The Companyโs principal activity is the development and sale of digital audiovisual (AV) networking solutions. Dante is its technology platform that distributes digital audio and video signals over computer networks. Dante comprises software and chips, cards and modules that are sold to and integrated inside the AV products of its original equipment manufacturer (OEM) customers. The firm also provides a series of products and services to AV professionals, including AVIO adapters and management and control software. Its Dante IP networking solution is used extensively in the professional live sound, commercial installation, broadcast, public address, and recording industries. Dante replaces traditional analogue cables by transmitting synchronized AV signals across large distances to multiple locations at once, using nothing more than an ethernet cable.
๐ Performance (5Yr p.a)
4.51%
๐ Share price
$7.07 AUD
๐จ COMMERCIAL SERVICES & SUPPLIES
ANZ Group Holdings Ltd. operates as a non-operating holding company. The company operates in six divisions: Australia Retail, Australia Commercial, Institutional, New Zealand, Pacific, and Group Center. The Australia Retail division offers a range of banking services, such as home loans, deposits, credit cards and personal loans. The company also offers digital and Internet banking and phone banking. The Australia Commercial division provides a full range of banking products and financial services, including asset financing, across customer segments: small business owners and medium commercial customers. The Institutional division services government, global institutional and corporate customers across Australia, New Zealand and International. The New Zealand division provides personal banking and wealth management services. The Pacific division provides retail products for traditional relationship banking. The Group center supports the operating divisions, including technology, property, and risk management.
๐ Performance (5Yr p.a)
9.31%
๐ Share price
$29.02 AUD
โ๏ธ HIGH GOVERNANCE
๐ฆ BANKING
๐ฐ HIGH DIVIDEND
๐ HIGH PRICE GROWTH
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
๐ Performance (5Yr p.a)
21.60%
๐ Share price
$59.81 AUD
๐ HIGH PRICE GROWTH
๐บ๐ธ UNITED STATES
Want more shares? Try these...